Publications for Magnus Janzon
Co-author map based on ISI articles 2007-

Publications mentioned in social media 22 times*

Keywords

treatment ticagrelor stroke strategy stemi risk percutaneous pci patients myocardial infarction health frailty events cost-effectiveness coronary clinical artery administration abciximab

Journal Articles

Martin Henriksson, Elisabet Nikolic, Audun Ohna, Lars Wallentin and Magnus Janzon
  Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark
 
Altmetric usage: 3

  Scandinavian Cardiovascular Journal, 2014, 48(3), 138-147.

Tim Tödt, Ingela Thylén, Joakim Alfredsson, Eva Swahn and Magnus Janzon
  Strategies TO reduce time delays in patients with AcuTe coronary heart diasease treated with primary PCI - the STOP WATCH study: a multistage action research project
  BMJ Open, 2013, 3(3493), .
   Fulltext  PDF  

Niklas Ekerstad, Eva Swahn, Magnus Janzon, Joakim Alfredsson, Rurik Löfmark, Marcus Lindenberger, David Andersson and Per Carlsson
  Frailty is independently associated with 1-year mortality for elderly patients with non-ST-segment elevation myocardial infarction
  European Journal of Preventive Cardiology, 2013, , .

Lars-Åke Levin, Lars Wallentin, Lars Bernfort, David Andersson, Robert F. Storey, Gina Bergstrom, Carl-Johan Lamm, Magnus Janzon and Padma Kaul
  Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial
  Value in Health, 2013, 16(4), 574-580.
 Web of Science® Times Cited: 2

Martin Henriksson and Magnus Janzon
  Cost-effectiveness of ticagrelor in acute coronary syndromes
 
Altmetric usage: 1

  Expert review of pharmacoeconomics & outcomes research, 2013, 13(1), 9-18.
 Web of Science® Times Cited: 1

Thomas Davidson, Magnus Husberg, Magnus Janzon, Jonas Oldgren and Lars-Åke Levin
  Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
 
Altmetric usage: 4

  European Heart Journal, 2013, 34(3), 177-183.
 Web of Science® Times Cited: 11

Elisabet Nikolic, Magnus Janzon, Ole Hauch, Lars Wallentin and Martin Henriksson
  Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study
 
Altmetric usage: 10

  European Heart Journal, 2013, 34(3), 220-228.
 Web of Science® Times Cited: 19

Ulf Berglund, Lennart Nilsson and Magnus Janzon
  Abciximab bolus with optional infusion in intervention for ST-elevation myocardial infarction
 
Altmetric usage: 3

  Scandinavian Cardiovascular Journal, 2013, 47(4), 230-235.

Staffan Nilsson, Per O. Andersson, Lars Borgquist, Ewa Grodzinsky, Magnus Janzon, Magnus Kvick, Eva Landberg, Håkan Nilsson and Jan-Erik Karlsson
  Point-of-Care Troponin T Testing in the Management of Patients with Chest Pain in the Swedish Primary Care
 
Altmetric usage: 1

  International Journal of Family Medicine, 2013, 2013, .
   Fulltext  PDF  

Tim Tödt, Eva Maret, Joakim Alfredsson, Magnus Janzon, Jan Engvall and Eva Swahn
  Relationship between treatment delay and final infarct size in STEMI patients treated with abciximab and primary PCI
  BMC Cardiovascular Disorders, 2012, 12(9), 1-9.
   Fulltext  PDF  

Artur Dziewierz, Waldemar Mielecki, Zbigniew Siudak, Tomasz Rakowski, Magnus Janzon, Ralf Birkemeyer, Wojciech Zasada, Jacek S. Dubiel and Dariusz Dudek
  Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry)
  Atherosclerosis, 2012, 223(1), 212-218.
 Web of Science® Times Cited: 1

Tomasz Rakowski, Zbigniew Siudak, Artur Dziewierz, Ralf Birkemeyer, Magnus Janzon, Waldemar Mielecki, Krzysztof Zmudka, Jacek S Dubiel and Dariusz Dudek
  Impact of infarct related artery patency after early abciximab administration on one-year mortality in patients with ST-segment elevation myocardial infarction (data from the EUROTRANSFER Registry)
  Kardiologia polska, 2012, 70(3), 215-221.
 Web of Science® Times Cited: 1

Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
  The Cost of Thromboembolic Events and their Prevention among Patients with Atrial Fibrillation
  Journal of Atrial Fibrillation, 2011, 2(4), 00-00.

Niklas Ekerstad, Eva Swahn, Magnus Janzon, Joakim Alfredsson, Rurik Löfmark, Marcus Lindenberger and Per Carlsson
  Frailty Is Independently Associated With Short-Term Outcomes for Elderly Patients With Non-ST-Segment Elevation Myocardial Infarction
  Circulation, 2011, 124(22), 2397-2404.
   Fulltext  PDF  
 Web of Science® Times Cited: 25

Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
  Compilation of cost-effectiveness evidence for different heart conditions and treatment strategies
  Scandinavian Cardiovascular Journal, 2011, 45(2), 72-76.
   Fulltext  PDF  

Sofia Lawesson, Tim Tödt, Joakim Alfredsson, Magnus Janzon, Ulf Stenestrand and Eva Swahn
  Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
  Heart, 2011, 97(4), 308-314.
   Fulltext  PDF  
 Web of Science® Times Cited: 10

Alexander Bufe, Ferrari Emile, Laurent Drogoul, Josep Guindo Soldevila, Di Pasquale Guiseppe, Lettino Maddalena, Magnus Janzon and Ruth E. Brown
  Costs of bleeds relating to acute coronary syndrome therapies.
  Journal of Medical Economics, 2010, 13(2), 236-240.

H Hemingway, Martin Henriksson, R. Chen, J. Damant, N. Fitzpatrick, K. Abrams, A. Hingorani, Magnus Janzon, M. Shipley, G. Feder, B. Keogh, Ulf Stenestrand, K. McAllister, J-C Kaski, A. Timmis, S. Palmer and M. Sculpher
  The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model.
  Health Technology Assessment, 2010, 14(9), .
 Web of Science® Times Cited: 8

Artur Dziewierz, Zbigniew Siudak, Tomasz Rakowski, Michal Chyrchel, Waldemar Mielecki, Magnus Janzon, Ralf Birkemeyer, Roman M Wojdyla, Jacek S Dubiel and Dariusz Dudek
  Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in elderly patients transferred with ST-elevation myocardial infarction Data from the EUROTRANSFER registry
  INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 143(2), 147-153.
 Web of Science® Times Cited: 6

Mikael Aasa, Martin Henriksson, Mikael Dellborg, Lars Grip, Johan Herlitz, Lars-Åke Levin, Leif Svensson and Magnus Janzon
  Cost and health outcome of primary percutaneous coronary intervention versus thrombolysis in acute ST-segment elevation myocardial infarction-Results of the Swedish Early Decision reperfusion Study (SWEDES) trial
  AMERICAN HEART JOURNAL, 2010, 160(2), 322-328.
 Web of Science® Times Cited: 6

Tim Tödt, Sofia Sederholm-Lawesson, Ulf Stenestrand, Joakim Alfredsson, Magnus Janzon and Eva Swahn
  Early treatment with abciximab in patients with ST elevation myocardial infarction results in a high rate of normal or near normal blood flow in the infarct related artery
  Acute cardiac care, 2010, 12(1), 10-17.

Zbigniew Siudak, Tomasz Rakowski, Artur Dziewierz, Magnus Janzon, Ralf Birkemeyer, Justyna Stefaniak, Lukasz Partyka, Krzysztof Zmudka and Dariusz Dudek
  Early abciximab use in ST-elevation myocardial infarction treated with primary percutaneous coronary intervention improves long-term outcome. Data from EUROTRANSFER Registry
  KARDIOLOGIA POLSKA, 2010, 68(5), 539-545.
 Web of Science® Times Cited: 12

Martin Henriksson, Jacqueline Damant, Natalie K Fitzpatrick, Keith Abrams, Aroon D Hingorani, Ulf Stenestrand, Magnus Janzon, Gene Feder, Bruce Keogh, Martin J Shipley, Juan-Carlos Kaski, Adam Timmis, Mark Sculpher and Harry Hemingway
  Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery
  BRITISH MEDICAL JOURNAL, 2010, 340, .
 Web of Science® Times Cited: 19

Ulla Walfridsson, Anna Strömberg, Magnus Janzon and Håkan Walfridsson
  Wolff-Parkinson-White Syndrome and Atrioventricular Nodal Re-Entry Tachycardia in a Swedish Population: Consequences on Health-Related Quality of Life
  Pacing and Clinical Electrophysiology, 2009, 32(10), 1299-1306.
 Web of Science® Times Cited: 4

J Knot, P Widimsky, W Wijns, Ulf Stenestrand, SD Kristensen, A Van´T Hof, F Weidinger, Magnus Janzon, BL Nörgaard, JT Soerensen, van de Wetering, K Thygesen, PA Bergsten, C Digerfeldt, A Potgieter, N Tomer and Fajadet
  How to set up an effective national primary angioplasty network: Lessons learned from five European countries
  EuroIntervention, 2009, 3(299), 301-309.
 Web of Science® Times Cited: 21

Tomasz Rakowski, Zbigniew Siudak, Artur Dziewierz, Ralf Birkemeyer, Jacek Legutko, Waldemar Mielecki, Rafal Depukat, Magnus Janzon, Justyna Stefaniak, Krzysztof Zmudka, Jacek S Dubiel, Lukasz Partyka and Dariusz Dudek
  Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER Registry
  AMERICAN HEART JOURNAL, 2009, 158(4), 569-575.
 Web of Science® Times Cited: 30

Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Guillermo Aldama-Lopez, Corrado Lettieri, Bogdan Janus, Andrzej Wisniewski, Sergio Becrti, Zoran Olivari, Tomasz Rakowski, Lukasz Partyka, Jochen Goedicke and Krzysztof Zmudka
  European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus an early administration of abciximab-EUROTRANSFER Registry
  American Heart Journal, 2008, 156(6), 1147-1154.
 Web of Science® Times Cited: 39

Urban Alehagen and Magnus Janzon
  A clinician’s experience of using the Cardiac Reader NT-proBNP point-of-care assay in a clinical setting
  European Journal of Heart Failure, 2008, 10(3), 260-266.
   Fulltext  PDF  
 Web of Science® Times Cited: 9

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Invasive treatment in unstable coronary artery disease promotes health-related quality of life: results from the FRISC II trial
  American Heart Journal, 2004, 148(1), 114-121.
 Web of Science® Times Cited: 19

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cost effectiveness of extended treatment with low molecular weight heparin (dalteparin) in unstable coronary artery disease: results from the FRISC II trial
  Heart, 2003, 89(3), 287-292.
 Web of Science® Times Cited: 4

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Comment concerning 'Cost-effectiveness of an invasive strategy in unstable coronary artery disease' - Reply
  European Heart Journal, 2002, 23(20), .

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cost-effectiveness of an invasive strategy in unstable coronary artery disease: results from the FRISC II invasive trial
  European Heart Journal, 2002, 23(1), 31-40.
 Web of Science® Times Cited: 26

Books

Lars-Åke Levin, Karin Sennfält, Magnus Janzon, Martin Henriksson, Agneta Andersson and Lars Bernfort
  En introduktion i hälsoekonomi
  AstraZeneca Sverige AB, 2004.


Chapters in Books

Magnus Janzon
  How to Organize Networks for Invasive Treatment of STEMI: Linköping Experience
  Mechanical reperfusion for STEMI: from randomized trials to clinical practice, Informa Healthcare, 2010, 41-49.


Conference Articles

Håkan Walfridsson, J Cosedis Nielsen, A Johannessen, P Raatikainen, J Hartikainen, Ulla Walfridsson, Lars-Åke Levin, Magnus Janzon, M Aronsson and P S Hansen
  Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden
  ESC Congress 2013, 31 August - 04 September 2013, Amsterdam, Netherlands, 2013.


M Aronsson, Magnus Janzon, Håkan Walfridsson, Ulla Walfridsson and Lars-Åke Levin
  Cost-effectivesness of catheter ablation as first-line treatment for paroxysmal atrial fibrillation
  On behalf of the MANTRA-RAP study Group, 2013.


Tim Tödt, Ingela Thylén, Joakim Alfredsson, Eva Swahn and Magnus Janzon
  Strategies to reduce time delays in patients with acute coronary heart disease treated with primary PCI.
  ESC Congress 2013, 2013.


Stefan K James, Robert F Storey, Christopher Cannon, Magnus Janzon, Jose C Nicoloau, Bhash Parasuraman, Carl Mellström and Martin Henriksson
  Health economic evalatuion of ticagrelor compared to generic clopidogrel in patients with acute coronary syndromes (ACS) intended for non-invasive management based on the PLATO trial
  ESC Congress 2013, 31 August - 04 September 2013, Amsterdam, Netherlands, 2013.


Kerstin Arbring, Roza Chaireti, Magnus Janzon, Srinivas Uppugunduri, Kjell Jansson and Tomas Lindahl
  First experience of structured introduction of new oral anticoagulants in a Swedish health care district: dabigatran as an alternative to warfarin in atrial fibrillation
  XXIVth Congress of the International Society of Thrombosis and Haemostasi (ISTH 2013), 29 June - 4 Juli 2013, Amsterdam, Holland, 2013.


Niklas Ekerstad, Eva Swahn, Magnus Janzon, Joakim Alfredsson, Rurik Löfmark, Marcus Lindenberger and Per Carlsson
  Frailty is independently associated with short-term outcomes for elderly patients with non-st-segment elevation myocardial infarction
  17th World Congress on Heart Disease (International Academy of Cardiology ), Annual Scientific Sessions 2012, 27-30 July 2012, Toronto, Canada, 2012.


Magnus Janzon
  Hälsoekonomiska effekter - fokus på nya antikoagulantia.
  XIV Svenska Kardiovaskulära Vårmötet, 2012.


Magnus Janzon
  Våra rutinbehaldningar - hur kostnadseffektiva är de? fokus på trombocythämmare.
  XIV Svenska Kardiovaskulära Vårmötet, 2012.


Tim Tödt, Eva Maret, Joakim Alfredsson, Magnus Janzon, Jan Engvall and Eva Swahn
  Relationship between the duration of ischemia and final infarct size in STEMI patients treated with abciximab and primary PCI.
  Journal of Cardiovascular Magnetic Resonance. SMCR, Orlando, Florida, 2012.


Magnus Janzon
  Primary angioplasty: The paradox of an intervention that improves outcome and reduces cost.
  Treatment of Acute Myocardial Infarction in Europe: Review of current models and proposal of optimal common standards., 2011.


Magnus Janzon
  Implementing the guidelines at a local (national) level. Workshop sessions.
  ACS Forum 2011, 2011.


Anders Jeppsson and Magnus Janzon
  SWEDEHEART - symposium.
  XIII Svenska Kardiovaskulära Vårmötet i Örebro, 2011.


Tim Tödt, Eva Maret, Joakim Alfredsson, Magnus Janzon, Jan Engvall and Eva Swahn
  Relationship between ischemia duration and final infarct size in STEMI patients treated with prehospital abciximab and primary PCI.
  XIII Svenska Kardiovaskulära Vårmötet i Örebro, 2011.


Staffan Nilsson, Pär Andersson, Magnus Janzon, Jan-Erik Karlsson and Lars Borgquist
  Efficiency of point-of-care Troponin-T testing in a Swedish primary care setting
  European Primary Care Cardiovascular Society 4th Annual Scientific Meeting, September 1-2, 2011, Berlin, Germany, 2011.


M. Henriksson, Elisabet Nikolic, Magnus Janzon, O. Hauch, Lars-Åke Levin and L. Wallentin
  LONG-TERM COSTS AND HEALTH OUTCOMES OF TREATING ACUTE CORONARY SYNDROME PATIENTS WITH TICAGRELOR BASED ON THE EU LABEL - COST-EFFECTIVENESS ANALYSIS BASED ON THE PLATO STUDY in VALUE IN HEALTH, vol 14, issue 3, pp A40-A40
  VALUE IN HEALTH, 2011.


 Web of Science® Times Cited: 2

Magnus Janzon
  STEMI 2010 - bästa behandling? Moderator på symposium
  XII Svenska Kardiovaskulära Vårmötet i Göteborg, 2010.


Magnus Janzon, Elisabet Nikolic, Martin Henriksson, Lars-Åke Levin, Ole Hauch, DB Mark, P. Cowper, P. Kaul, RA. Harrington, J. Horrow and Lars Wallentin
  Health Economics in the PLATelet Inhibition and Patient Outcomes (PLATO) Randomized Trial: Report on Within Trial Resource Use Patterns
  The American Heart Association 2010 Scientific Sessions, Chicago, IL, USA, November 13-17 2010, 2010.


Z Siudak, R Birkemeyer, T Rakowski, A Dziewierz, Magnus Janzon, J Skowronek, P Ranosz, J S Dubiel and D Dudek
  Out-of-hospital cardiac arrest in patients treated with primary PCI for STEMI. Long-term follow up data from EUROTRANSFER registry in EUROPEAN HEART JOURNAL, vol 31, issue , pp 900-900
  EUROPEAN HEART JOURNAL, 2010.


Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
  Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for hearts diseases (Abstract)
  Value in Health, 2010.


Nathalie Eckard, Magnus Janzon and Lars-Åke Levin
  Communicating cost-effectiveness ratios to decision makers - the case of the Swedish national guidelines for heart diseases (Poster)
  ISPOR 13th Annual European Congress. Prag Tjeckien, 2010.


Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
  The cost of atrial fibrillation in Sweden (Poster)
  Value in Health, 2010.


Eva Maret, Lars Brudin, Magnus Janzon, J Ohlsson and Jan Engvall
  High sensitivity and specificity for detecting transmural infarction with a feature tracking software on cine MRI.
  ESC Barcelona 2009, 2009.


Harry Hemingway, Ruoling Chen, Jacqueline Damant, Natalie Fitzpatrick, Aroon Hingorani, Bruce Keogh, Kate McAllister, Martin Henriksson, Keith Abrams, Magnus Janzon, Ulf Stenestrand, Juan-Carlos Kaski, Adam Timmis, Stephen Palmer and Mark Sculpher
  Cost-effectiveness of circulating biomarkers in managing stable coronary disease.
  SMDM,2008, 2008.


Stella Cizinsky, Rurik Löfmark and Magnus Janzon
  Etik och hälsoekonomi, när bot inte längre är möjligt
  Fortbildningsdagar i Kardiologi,2008, 2008.


Zahar Shakeri, Malin Hammar-Henriksson, Joakim Alfredsson and Magnus Janzon
  Evaluating cardiodetect with card test for early diagnosis of acute myocardial infarction.
  X Svenska Kardiovaskulära Vårmöte,2008, 2008.


Tomasz Rakowski, Artur Dziewierz, Zbigniew Siudak, Waldemar Mielecki, Jacek Legutko, Magnus Janzon, Ralf Birkemeyer, Rafal Depukat and Dariusz Dudek
  Early Abciximab administration before primary percutaneous coronary interventions reduces mortality but not in low-risk patients. Results from EUROTRANSFER registry on ST-elevation myocardial infarction patients.
  ACC - 57th Annual Scientific Session,2008, 2008.


W Mielecki, Z Siudak, T Rakowski, A Dziewierz, Magnus Janzon, R Birkemeyer, D Dykla, J Zdzienicka and D Dudek
  Early abcizimab administration before primary angioplasty influences 30-day clinical outcome in diabetic patients with ST-elevation myocardial infarction
  ESC Congress,2008, 2008.


Z Siudak, Magnus Janzon, R Birkemeyer, T Rakowski, A Dziewierz, P Kleczynski, W Mielecki and D Dudek
  Radial approach in STEMI patients treated with primary PCI with abciximab is safer than femoral in terms of local access site complications. Date from EUROTRANSFER registry.
  ESC Congress,2008, 2008.


Helene Zachrisson, Anders Persson, Jan Engvall, Ulf Stenestrand and Magnus Janzon
  CT angiography - clinical experience from Linköping University Hospital
  X Svenska Kardiovaskulära Vårmötet,2008, 2008.


Jacek Legutko, Tomasz Rakowski, Zbigniew Siudak, Lukasz Rzeszutko, Magnus Janzon, Ralf Birkemeyer, Pawel Kleczynski and Dariusz Dudek
  Efficacy and safety of early clopidogrel administration with or without Abciximab in patients with ST-segment elevation myocardial infarction transferred for primary PCI. Results from the EUROTRANSFER registry.
  ACC - 57th Annual Scientific Session,2007, 2008.


Zbigniew Siudak, Tomasz Rakowski, Artur Dziewierz, Wojciech Zasada, Michal Brzezinski, Magnus Janzon, Ralf Birkemeyer and Darius Dudek
  Primary percutaneous coronary intervention performed during nightshift hours was associated with increased in-hospital mortality in patients with ST elevation myocardial infarction. Results from EUROTRANSFER registry.
  ACC - 57th Annual Scientific Session,2008, 2008.


Joakim Alfredsson, Anna Käll, Hanna Tilander, Magnus Janzon, Eva Swahn and Lena Jonasson
  Sex matters-lipid goal achievement in a population admitted to a coronary care unit
  X Svenska Kardiovaskulära Vårmötet,2008, 2008.


Martin Henriksson, Magnus Janzon, M. Aasa, Elisabet Lundborg (Nikolic), L. Svensson, J. Herlitz, L. Grip and Lars-Åke Levin
  Cost-effectiveness of very early treatment strategies for acute ST-elevation myocardial infarction based on the Swedish early decision (SWEDES) reperfusion trial (oral presentation)
  SMDM Europe,2008, 2008.


Zbigniew Siudak, Artur Dziewierz, Tomasz Rakowski, Sergio Berti, Zoran Olivari, Magnus Janzon, Ralf Birkemeyer and Dariusz Dudek
  By-passing Emergency Room Shortens Time Delays in STEM I Patients Transferred for Primary PCI. Results From EUROTRANSFER Registry, Washington DC, USA
  AMERICAN JOURNAL OF CARDIOLOGY,ISSN 0002-9149, Transcatheter Cardiovascular Therapeutics  Abstracts: Volume 102, Issue 8A, 2008.


 Web of Science® Times Cited: 1

Zbigniew Studak, Tomasz Rakowski, Artur Dziewierz, Magnus Janzon, Ralf Birkemeyer, Sergio Berti, Lukasz Partyka, Krzysztof Zmudka and Dariusz Dudek
  Primary PCI Performed With Delay > 90 Minutes From Diagnosis Seems Acceptable in Terms of Short- and Long-Term Clinical Outcome. One Year Results From EUROTRANSFER Registry,Washington DC, USA
  AMERICAN JOURNAL OF CARDIOLOGY,ISSN 0002-9149 Transcatheter Cardiovascular Therapeutics  Abstracts: Volume 102, Issue 8A, 2008.


Magnus Janzon
  EUROTRANSFER and beyond - There is still a rationale for facilitation!
  ACS Network Workshop,2007, 2007.


Magnus Janzon
  STEMI treatment in the real world: Learning from RIKS-HIA and EuroTransfer
  PACS. Progress in Acute Coronary Syndromes,2007, 2007.


Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Krzysztof Zmudka, Roberto Zanini, Zoran Olivari, Sergio Berti and Leonardo Bolognese
  Primary PCI performed with delay <120 minutes from diagnosis seems acceptable in terms of short-term clinical outcomes. Results from EUROTRANSFER registry.
  LCT,2007, 2007.


Magnus Janzon
  Grunder i hälsoekonomi. Exempel från kardiologin.
  Nationella fortbildningsdagar i kardiologi.,2007, 2007.


Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Krzysztof Zmudka, Corrado Lettieri, Guillermo Aldama, Andrzej Wisniewski, Bogdan Janus and Lukasz Partyka
  Determinants of outcomes in patients with ST elevation myocardial infarction (STEMI) transferred for primary PCI. Results from the EUROTRANSFER registry.
  ESC,2007, 2007.


Dariusz Dudek, Zbigniew Siudak, Magnus Janzon, Ralf Birkemeyer, Krzysztof Zmudka, Corrado Lettieri, Guillermo Aldama, Andrzej Wisniewski, Bogdan Janus and Lukasz Partyka
  EUROTRANSFER Registry. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion (PCI) with a special focus on upstream use of abciximab.
  ESC,2007, 2007.


Magnus Janzon
  Novel Strategies for the Management of STEMI
  Kardiologen, US som ett led i vår utmärkelse Center of Excellence Europé 2007 möte med läkare från Holland,2007, 2007.


Ulla Walfridsson, Anna Strömberg, Magnus Janzon and Håkan Walfridsson
  Paroxysmal supraventricular tachyarrhythmia in a Swedish population: consequences on health-related quality of life
  European Society of Cardiology 2007,2007, 2007.


Magnus Janzon, Mikael Aasa, Johan Lyth, Leif Svensson, Johan Herlitz, Lars Grip and Lars-Åke Levin
  Cost and effectiveness comparison of very early treatment with primary percutaneous coronary intervention facilitated with abciximab or thrombolytic therapy for acute ST-elevation myocardial infarction
  ACC,2007, 2007.


Magnus Janzon
  Prehospital treatment - the role of thrombolytics, GPIIb/IIIa antagonists och thienopyridines?
  1st Pan-European STEMI Network Symposium,2007, 2007.


Magnus Janzon
  Antitrombotisk behandling prehospitalt vid primär PCI
  IX Svenska Kardiovaskulära Vårmötet,2007, 2007.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Invasive treatment in non ST elevation acute coronary syndorme promotes long-term health related quality of life - results from the FRISC II trial
  ACC, New Orleans, LA,2007, 2007.


Magnus Janzon
  STEMI - Primär PCI Östgötamodellen. Uppbyggnad och resultat.
  Nationellt Thoraxmöte i Linköping,2006, 2006.


Magnus Janzon
  Bröstsmärtor på akuten, akut koronart syndorm. Vad ska göras, när?
  Nationellt Akutläkarmöte i Linköping,2006, 2006.


Magnus Janzon
  Den kostnadseffektiva revaskulariseringen, finns den?
  VIII Svenska Kardiovaskulära Vårmötet,2006, 2006.


Ioan Liuba, Magnus Janzon, Ulla Walfridsson and Håkan Walfridsson
  Impact of catheter ablation on health related quality of life in patients with focal atrial tachycardia
  VIII Svenska Kardiovaskulära Vårmötet,2006, 2006.


Magnus Janzon
  Hälsoekonomiska och sjukvårdsrelaterade synpunkter vid antitrombotisk behandling vid kranskärlssjukdom
  VIII Svenska Kardiovaskulära Vårmötet,2006, 2006.


Jan Wigren, Christer Carlsson, Ingela Johansson, Magnus Janzon and Anders Broström
  Patient´s perceptions of prehospital care during acute myocardial infarction
  NSFS Landsgruppe av Kardiologiske sykepleiere,2006, 2006.


Martin Henriksson, Anders Nordlund, Magnus Janzon and Eva Swahn
  A comparison of EQ-5D and SF-6D utilities
  iHEA 2003, San Francisco. Muntlig posterpresentation,2003, 2003.


Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable angina - Individual and public preferences differ in levels but are similar when measuring changes over time
  European Heart Journal, 2002.


Magnus Janzon, Martin Henriksson, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable angina. Individual and public preferences differ in levels but are similar when measuring changes over time
  ISTAHC-konferens, Berlin, juni 2002,2002, 2002.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cost-effectiveness of early invasive treatment in unstable coronary artery disease: A one-year follow-up from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2001.


 Web of Science® Times Cited: 1

Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Quality of life one year after invasive intervention in unstable coronary artery disease: Results from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2001.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Cast-comparison of early invasive versus non-invasive treatment in unstable coronary artery disease - A six months follow-up from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2000.


Magnus Janzon, Lars-Åke Levin and Eva Swahn
  Quality of life in unstable coronary artery disease - A comparison of early invasive versus non-invasive treatment. Six months follow-up from the FRISC II invasive trial
  Journal of the American College of Cardiology, 2000.


L Wallentin, E Diderholm, Magnus Janzon, F Kontny, B Lagerqvist, B Lindahl, S Husted and Eva Swahn
  The protective effects of long-term lmw heparin (dalteparin) treatment in unstable CAD is confined to patients not previously treated with statins
  European Heart Journal, 2000.


L Wallentin, E Diderholm, Magnus Janzon, F Kontny, B Lagerqvist, S Husted and Eva Swahn
  Elevation of LDL cholesterol and interaction with the cholesterol lowering effect of statins during long-term low-molecular-weight heparin (dalteparin) treatment
  European Heart Journal, 2000.


Ph.D. Theses

Tim Tödt
  Strategies to improve outcome in patients with ST elevation myocardial infarction treated with primary PCI
  2012.


  Fulltext PDF

Magnus Janzon
  Treatment strategies in unstable coronary artery disease: economic and quality of life evaluations
  2003.


Reports

Thomas Davidson, Magnus Husberg, Magnus Janzon and Lars-Åke Levin
  CMT rapport: kostnader och kostnadseffektivitet av ett införande av dabigatran hos patienter med förmaksflimmer
  CMT Rapport, 2011:1, 2011.


  Fulltext PDF

* Social media data based on publications from 2011 to present and with a DOI; data delivered by Altmetric.com.